VANCOUVER, British Columbia--(BUSINESS WIRE)--Jun 1, 2023--
Canadian life sciences company Ondine Biomedical has appointed Dr. Simon Sinclair as Chief Medical Officer, as the Company prepares to start the US Phase 3 trial of its nasal photodisinfection technology. Dr Sinclair has over 20 years of pharma and medtech experience across translational medicine, clinical development, medical affairs, market access, and medical safety and vigilance. Dr Sinclair has served as a non-executive director on Ondine's Board of Directors since 2021.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230601005719/en/
Dr Simon Sinclair (Photo: Business Wire)
Ondine's CEO, Carolyn Cross, said:
"We are delighted to have Simon join Ondine at this critical time for the Company, as we prepare to start our major Phase 3 trial in the US and escalate our clinical and commercialization efforts in other major markets. Simon's extensive pharmaceutical and medical device experience, as well as his familiarisation with Ondine's products and strategy as a member of our board, makes him the ideal person to help us to achieve our aim of implementing our life-saving photodisinfection technology in healthcare systems across the world."
Dr. Sinclair joins Ondine having held senior positions at major Pharma and MedTech companies, including Johnson and Johnson Medical Devices, where he was International Clinical Director and then led Medical Affairs across the EMEA region. Prior to this, Dr Sinclair led translational medicine efforts and early clinical development at Merck and Co (MSD) in the USA, where he served as Senior Director Clinical Research and subsequently Head of Global Trial Optimization.
Dr. Sinclair said:
"Having been closely involved with Ondine at board level, I am excited to join the Company in an operational capacity at this critical stage, as we plan for entry into the US Phase 3 trial and see growing interest and adoption in other key markets.
He continued:
"Multi-drug resistant infections are an existential global healthcare threat, and there has never been a more important time to focus on new, non-antibiotic solutions. I look forward to working with the Ondine team to bring its photodisinfection technology through the FDA regulatory process in the US and continuing to build usage and implementation across the countries where we already have approval, including Canada, EU and UK."
In his previous role as Chief Safety Officer at Reckitt, Dr. Sinclair was responsible for the safety of the multibillion dollar Reckitt portfolio, with the goal of building and maintaining consumers' trust in Reckitt products.
Beyond his medical degree focusing in Opthalmology as well as his pharmaceutical and Medical Device development experience, Dr. Sinclair is an established scientist with a PhD in neural transplantation from Cambridge University and a BSc in neuroscience from King's College London. He has published numerous medical and scientific abstracts and papers throughout his career.
**ENDS**
About Ondine Biomedical Inc.
Ondine Biomedical Inc. is a Canadian headquartered life sciences company that is the leader in photodisinfection therapies. Ondine has a pipeline of investigational products based on its proprietary photodisinfection platform, in various stages of development. Products beyond nasal photodisinfection include treatments for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns, and other indications.
About photodisinfection
Ondine's photodisinfection is a patented technology using a proprietary photosensitizer (non-antibiotic, light-activated solution) to destroy pathogens. When illuminated with a specific wavelength of light, the photosensitizer is activated, causing an oxidative burst that is lethal to all types of pathogens. Ondine's nasal photodisinfection system has a CE mark and is approved in Canada and several other countries under the name Steriwave™. It has been used in Canada for over ten years, with no serious adverse events reported. In the US, it is currently undergoing clinical trials for regulatory approval.
View source version on businesswire.com:https://www.businesswire.com/news/home/20230601005719/en/
CONTACT: Ondine Biomedical Inc.
Angelika Vance, Corporate Communications
+001 (604) 838 2702
Singer Capital Markets (Nominated Adviser and Joint Broker)
Aubrey Powell, Asha Chotai, Sam Butcher
+44 (0)20 7496 3000
RBC Capital Markets (Joint Broker)
Rupert Walford, Kathryn Deegan
+44 (0)20 7653 4000
Vane Percy & Roberts (Media Contact)
Simon Vane Percy, Amanda Bernard
+44 (0)77 1000 5910
KEYWORD: NORTH AMERICA CANADA
INDUSTRY KEYWORD: BIOTECHNOLOGY MEDICAL DEVICES HEALTH PHARMACEUTICAL CLINICAL TRIALS
SOURCE: Ondine Biomedical
Copyright Business Wire 2023.
PUB: 06/01/2023 09:40 AM/DISC: 06/01/2023 09:40 AM
http://www.businesswire.com/news/home/20230601005719/en
